有色皮肤 (SoC) 的人与浅色皮肤的人相比,寻常痤疮 (AV) 的临床表现和对治疗药物的反应可能有所不同。鉴于炎症后色素沉着过度和瘢痕疙瘩发展的可能性增加,对 SoC 患者进行有效和及时的 AV 治疗尤为重要。然而,这些患者在临床试验中的代表性不足,而 SoC 照片在皮肤科中的代表性通常不足。Trifarotene 0.005% 乳膏是一种被批准用于每日一次局部治疗 AV 的类视黄醇,并在评估面部和躯干 AV 治疗的大规模临床试验中进行了研究。对于严重的 AV,可将局部类视黄醇与口服抗生素(如强力霉素)联合使用。涵盖 Fitzpatrick 皮肤光型 III、IV、V 和 VI 选自两项较大的研究,以直观地证明用 0.005% 的曲法罗汀乳膏治疗临床诊断的 AV。两名受试者接受了 24 周的 0.005% 曲法罗汀乳膏治疗面部和躯干的中度 AV,而三名受试者接受了 12 周的曲法罗汀 0.005% 乳膏联合 120 mg 口服多西环素和改性聚合物涂层治疗重度面部 AV。本案例系列支持使用 0.005% 曲法罗汀乳膏(联合或不联合口服强力霉素)对 SoC 受试者(光型 III-VI)进行面部和躯干 AV 治疗的良好疗效和安全性。用于面部和躯干的中度 AV 的 005% 乳膏,而三名受试者接受 12 周的三法罗汀 0.005% 乳膏联合 120 mg 口服多西环素和改性聚合物涂层用于重度面部 AV。本案例系列支持使用 0.005% 曲法罗汀乳膏(联合或不联合口服强力霉素)对 SoC 受试者(光型 III-VI)进行面部和躯干 AV 治疗的良好疗效和安全性。用于面部和躯干的中度 AV 的 005% 乳膏,而三名受试者接受 12 周的三法罗汀 0.005% 乳膏联合 120 mg 口服多西环素和改性聚合物涂层用于重度面部 AV。本案例系列支持使用 0.005% 曲法罗汀乳膏(联合或不联合口服强力霉素)对 SoC 受试者(光型 III-VI)进行面部和躯干 AV 治疗的良好疗效和安全性。
"点击查看英文标题和摘要"
Trifarotene 0.005% Cream in the Treatment of Facial and Truncal Acne Vulgaris in Patients with Skin of Color: a Case Series
The clinical appearance of acne vulgaris (AV) and the response to therapeutic agents may vary in people with skin of color (SoC) compared with those with lighter skin types. Given the heightened potential for postinflammatory hyperpigmentation and keloid development, effective and timely AV treatment in patients with SoC is especially important. However, these patients are frequently underrepresented in clinical trials, and SoC photographs are generally underrepresented in dermatology. Trifarotene 0.005% cream is a retinoid approved for the once-daily topical treatment of AV, and was studied in large-scale clinical trials that assessed the treatment of AV on both the face and trunk. For severe AV, a topical retinoid may be used in combination with an oral antibiotic, such as doxycycline. Five subjects covering Fitzpatrick skin phototypes III, IV, V, and VI were selected from two larger studies to visually demonstrate treatment of clinically diagnosed AV with trifarotene 0.005% cream. Two subjects received 24 weeks of treatment with trifarotene 0.005% cream for moderate AV on the face and trunk, while three subjects received 12 weeks of treatment with trifarotene 0.005% cream in association with 120 mg oral doxycycline with modified polymer coating for severe facial AV. This case series supports the favorable efficacy and safety of facial and truncal AV treatment with trifarotene 0.005% cream, with or without oral doxycycline, in subjects with SoC (phototypes III–VI).